Dextrothyroxine: Difference between revisions
No edit summary |
m (Protected "Dextrothyroxine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
(One intermediate revision by one other user not shown) | |||
Line 53: | Line 53: | ||
==Overview== | ==Overview== | ||
'''Dextrothyroxine''' (trade name '''Choloxin''') saw research as an cholesterol-lowering drug | '''Dextrothyroxine''' (trade name '''Choloxin''') saw research as an cholesterol-lowering drug but was pulled due to cardiac side-effects. It also increases [[hepatic lipase]] which in turn improves utilization of triglycerides, improving [[apolipoprotein E]] cholesterol particles. | ||
==See Also== | ==See Also== |
Latest revision as of 19:49, 18 August 2015
Clinical data | |
---|---|
Trade names | Choloxin |
Synonyms | D-3,5,3',5'-tetraiodothyronine |
AHFS/Drugs.com | Multum Consumer Information |
Pregnancy category |
|
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C15H11I4NO4 |
Molar mass | 776.87 g/mol |
3D model (JSmol) | |
| |
|
WikiDoc Resources for Dextrothyroxine |
Articles |
---|
Most recent articles on Dextrothyroxine Most cited articles on Dextrothyroxine |
Media |
Powerpoint slides on Dextrothyroxine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Dextrothyroxine at Clinical Trials.gov Trial results on Dextrothyroxine Clinical Trials on Dextrothyroxine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Dextrothyroxine NICE Guidance on Dextrothyroxine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Dextrothyroxine Discussion groups on Dextrothyroxine Patient Handouts on Dextrothyroxine Directions to Hospitals Treating Dextrothyroxine Risk calculators and risk factors for Dextrothyroxine
|
Healthcare Provider Resources |
Causes & Risk Factors for Dextrothyroxine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dextrothyroxine (trade name Choloxin) saw research as an cholesterol-lowering drug but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.
See Also
References
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without KEGG source
- Articles containing unverified chemical infoboxes
- Drug
- Cardiovascular Drugs
- Hypolipidemic agents